BNO
Bionomics
- Short interest
- 0.12%
- +0.12 pp 30d
- as of 11 Sept 2023
- Reported shorts
- 1.8M
- Shares on issue
- 1.469B
Bionomics (BNO) company profile
Profile, insiders and operations
Company
AI-generated research profile of Bionomics
Biopharmaceutical
Neuroscience
Clinical Trials
Drug Development
ASX Listed
Bionomics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel drug candidates for central nervous system (CNS) disorders. Their primary focus is on anxiety, depression, and other neurological conditions, leveraging their proprietary drug discovery platform. The company aims to address significant unmet medical needs through innovative therapeutic approaches, with a lead candidate in late-stage clinical trials.
Director trades
No director trades found
BNO intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required